Medication non-adherence is costing our industry billions – and patients their health.
Despite unprecedented innovation in therapeutics, too many patients still fail to realise the benefits of the medicines we develop. For pharma, that means lost impact, lost trust and lost value. For patients, it means avoidable deterioration in health and reduced quality of life. For healthcare providers it means greater load on services with appointments and admissions that could have been avoided.
At Cognitant, we believe the adherence challenge won’t be fixed by new molecules or more apps alone. It requires real insight into how patients actually live, the friction they face and the moments where support truly matters. That’s why we convened leading clinicians, behavioural scientists, patient voices and industry experts – alongside a comprehensive survey – to understand adherence from the ground up.
This white paper captures what we learned. It exposes the true commercial and clinical burden of non-adherence, but more importantly, the missed opportunities to drive better outcomes through patient-centred design, clearer communication and closer partnership between pharma and the wider health system.
For senior leaders shaping future strategy, the message is clear: Adherence is no longer a peripheral issue – it is a critical value driver. Those who invest in solving it will unlock better outcomes for patients and stronger performance across the entire lifecycle.
I hope these insights challenge and inspire new collaboration across our sector. By closing the gap between prescription and persistence, we can deliver on the full promise of the therapies we bring to market. To request a copy of the white paper simply complete the contact form on the right of this page
Dr Tim Ringrose
Chief Executive Officer, Cognitant